International Clinical Trial: Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07523711) titled 'Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity' on April 6.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Amgen

Condition: Overweight Obesity

Intervention: Drug: COC

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: April 9, 2026

Target Sample Size: 45

To know more, visit https://clinicaltrials.gov/study/NCT0752371...